{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T00:35:11Z","timestamp":1778978111563,"version":"3.51.4"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"am","delay-in-days":332,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RSPD2024R829"],"award-info":[{"award-number":["RSPD2024R829"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002383","name":"King Saud University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002383","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["P30 DA033934"],"award-info":[{"award-number":["P30 DA033934"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.bbr.2024.115019","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T15:34:38Z","timestamp":1714059278000},"page":"115019","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Nelotanserin, a selective 5-HT2A receptor inverse agonist, attenuates aspects of nicotine withdrawal but not reward in mice"],"prefix":"10.1016","volume":"467","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0031-7377","authenticated-orcid":false,"given":"Belle","family":"Buzzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shakir D.","family":"AlSharari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Walentiny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Imad","family":"Damaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bbr.2024.115019_bib1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1124\/jpet.109.160994","article-title":"Nelotanserin, a novel selective human 5-hydroxytryptamine2A inverse agonist for the treatment of insomnia","volume":"332","author":"Al-Shamma","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.bbr.2024.115019_bib2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1124\/jpet.109.160994","article-title":"Nelotanserin, a novel selective human 5-hydroxytryptamine2A inverse agonist for the treatment of insomnia","volume":"332","author":"Al-Shamma","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbr.2024.115019_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108009","article-title":"Suppression of cocaine relapse-like behaviors upon pimavanserin and lorcaserin co-administration","volume":"168","author":"Anastasio","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbr.2024.115019_bib4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.neuropharm.2013.09.025","article-title":"Nicotine dependence produces hyperalgesia: role of corticotropin-releasing factor-1 receptors (CRF1Rs) in the central amygdala (CeA)","volume":"77","author":"Baiamonte","year":"2014","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.bbr.2024.115019_bib5","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00213-004-2035-z","article-title":"Attenuation of nicotine\u2019s discriminative stimulus effects in rats and its locomotor activity effects in mice by serotonergic 5-HT2A\/2C receptor agonists.","volume":"179","author":"Batman","year":"2005","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.bbr.2024.115019_bib6","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/BF00435271","article-title":"Effects of chronic nicotine administration on the response and adaptation to stress","volume":"76","author":"Benwell","year":"1982","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bbr.2024.115019_bib7","first-page":"103","article-title":"CHAPTER 1.5\u2014Classification and signaling characteristics of 5-HT receptors.","volume":"Vol. 21","author":"Bockaert","year":"2010"},{"issue":"15","key":"10.1016\/j.bbr.2024.115019_bib8","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1080\/14656566.2016.1234609","article-title":"Pimavanserin for the treatment of Parkinson\u2019s disease psychosis","volume":"17","author":"Chendo","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"issue":"8","key":"10.1016\/j.bbr.2024.115019_bib9","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3181\/0712-MR-355","article-title":"Influence of neuronal nicotinic receptors over nicotine addiction and withdrawal","volume":"233","author":"De Biasi","year":"2008","journal-title":"Exp. Biol. Med."},{"issue":"7","key":"10.1016\/j.bbr.2024.115019_bib10","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/j.neuropharm.2012.01.023","article-title":"Effects of the 5-HT2C receptor agonist Ro60-0175 and the 5-HT2A receptor antagonist M100907 on nicotine self-administration and reinstatement","volume":"62","author":"Fletcher","year":"2012","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.bbr.2024.115019_bib11","first-page":"513","article-title":"Smoking cessation interventions","volume":"106","author":"Gaddey","year":"2022","journal-title":"Am. Fam. Physician"},{"issue":"10","key":"10.1016\/j.bbr.2024.115019_bib12","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/0028-3908(73)90027-0","article-title":"Alteration of 5-hydroxytryptamine-14C efflux by nicotine in rat brain area slices","volume":"12","author":"Goodman","year":"1973","journal-title":"Neuropharmacology"},{"issue":"5\u20136","key":"10.1016\/j.bbr.2024.115019_bib13","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1016\/j.neuropharm.2012.01.003","article-title":"The duration of nicotine withdrawal-associated deficits in contextual fear conditioning parallels changes in hippocampal high affinity nicotinic acetylcholine receptor upregulation","volume":"62","author":"Gould","year":"2012","journal-title":"Neuropharmacology"},{"issue":"10","key":"10.1016\/j.bbr.2024.115019_bib14","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1007\/s11064-014-1293-3","article-title":"On the discovery and development of pimavanserin: a novel drug candidate for parkinson\u2019s psychosis","volume":"39","author":"Hacksell","year":"2014","journal-title":"Neurochem. Res."},{"issue":"1","key":"10.1016\/j.bbr.2024.115019_bib15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0893-133X(00)00237-2","article-title":"Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats","volume":"25","author":"Harrison","year":"2001","journal-title":"Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol."},{"issue":"6","key":"10.1016\/j.bbr.2024.115019_bib16","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/0091-3057(83)90405-7","article-title":"Nicotine as a reinforcer in human subjects and laboratory animals","volume":"19","author":"Henningfield","year":"1983","journal-title":"Pharmacol., Biochem., Behav."},{"key":"10.1016\/j.bbr.2024.115019_bib17","first-page":"229","article-title":"Chapter 7\u20145-HT2A and 5-HT2C receptors as potential targets for the treatment of nicotine use and dependence","volume":"Vol. 259","author":"Higgins","year":"2021"},{"issue":"1","key":"10.1016\/j.bbr.2024.115019_bib18","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1124\/pr.114.009514","article-title":"Serotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder","volume":"67","author":"Howell","year":"2015","journal-title":"Pharmacol. Rev."},{"issue":"1","key":"10.1016\/j.bbr.2024.115019_bib19","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1124\/jpet.107.132977","article-title":"Differential role of nicotinic acetylcholine receptor subunits in physical and affective nicotine withdrawal signs","volume":"325","author":"Jackson","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.bbr.2024.115019_bib20","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","article-title":"Long-term follow-up of psilocybin-facilitated smoking cessation","volume":"43","author":"Johnson","year":"2017","journal-title":"Am. J. Drug Alcohol Abus."},{"issue":"7","key":"10.1016\/j.bbr.2024.115019_bib21","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/0269881116684335","article-title":"An online survey of tobacco smoking cessation associated with naturalistic psychedelic use","volume":"31","author":"Johnson","year":"2017","journal-title":"J. Psychopharmacol. (Oxf., Engl. )"},{"issue":"2","key":"10.1016\/j.bbr.2024.115019_bib22","first-page":"968","article-title":"Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile","volume":"277","author":"Kehne","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.bbr.2024.115019_bib23","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/BF02244308","article-title":"Prospective study of factors influencing the development of craving associated with smoking cessation","volume":"105","author":"Killen","year":"1991","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1016\/j.bbr.2024.115019_bib24","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/00002826-198708000-00009","article-title":"Effect of chronic nicotine administration on monoamine and monoamine metabolite concentrations in rat brain","volume":"10","author":"Kirch","year":"1987","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.bbr.2024.115019_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2019.134524","article-title":"Inverse agonists of the 5-HT2A receptor reduce nicotine withdrawal signs in rats","volume":"713","author":"Malin","year":"2019","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bbr.2024.115019_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fnbeh.2020.582147","article-title":"Drug-induced conditioned place preference and its practical use in substance use disorder research","volume":"14","author":"McKendrick","year":"2020","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.bbr.2024.115019_bib27","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-3-319-13482-6_4","article-title":"Nicotine withdrawal","volume":"24","author":"McLaughlin","year":"2015","journal-title":"Curr. Top. Behav. Neurosci."},{"issue":"7","key":"10.1016\/j.bbr.2024.115019_bib28","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1021\/acschemneuro.5b00023","article-title":"Cartography of 5-HT1A and 5-HT2A receptor subtypes in prefrontal cortex and its projections","volume":"6","author":"Mengod","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bbr.2024.115019_bib29","unstructured":"National Institute on Drug Abuse (NIDA). (2021) What are the physical health consequences of tobacco use? \u3008https:\/\/nida.nih.gov\/publications\/research-reports\/tobacco-nicotine-e-cigarettes\/what-are-physical-health-consequences-tobacco-use\u3009."},{"issue":"13","key":"10.1016\/j.bbr.2024.115019_bib30","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1016\/S0028-3908(00)00109-X","article-title":"Nicotinic receptors co-localize with 5-HT(3) serotonin receptors on striatal nerve terminals.","volume":"39","author":"Nayak","year":"2000","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.bbr.2024.115019_bib31","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","article-title":"Hallucinogens","volume":"101","author":"Nichols","year":"2004","journal-title":"Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.bbr.2024.115019_bib32","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s002130100710","article-title":"Behavioral and neurochemical consequences of repeated nicotine treatment in the serotonin-depleted rat","volume":"155","author":"Olausson","year":"2001","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.bbr.2024.115019_bib33","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0006-8993(03)03174-3","article-title":"In vivo pharmacological characterization of (\u00b1)-4-[2-(1-methyl-2-pyrrolidinyl)ethyl]thiophenol hydrochloride (SIB-1553A), a novel cholinergic ligand: microdialysis studies","volume":"986","author":"Rao","year":"2003","journal-title":"Brain Res."},{"issue":"2","key":"10.1016\/j.bbr.2024.115019_bib34","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0006-8993(93)90121-3","article-title":"Effects of systemic nicotine on serotonin release in rat brain","volume":"621","author":"Ribeiro","year":"1993","journal-title":"Brain Res."},{"issue":"2","key":"10.1016\/j.bbr.2024.115019_bib35","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0006-8993(93)90121-3","article-title":"Effects of systemic nicotine on serotonin release in rat brain","volume":"621","author":"Ribeiro","year":"1993","journal-title":"Brain Res."},{"issue":"2","key":"10.1016\/j.bbr.2024.115019_bib36","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0006-8993(93)90121-3","article-title":"Effects of systemic nicotine on serotonin release in rat brain","volume":"621","author":"Ribeiro","year":"1993","journal-title":"Brain Res."},{"issue":"15","key":"10.1016\/j.bbr.2024.115019_bib37","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2174\/138161211796197052","article-title":"Pharmacological advances in the treatment of insomnia","volume":"17","author":"Richey","year":"2011","journal-title":"Curr. Pharm. Des."},{"issue":"12","key":"10.1016\/j.bbr.2024.115019_bib38","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1093\/sleep\/31.12.1663","article-title":"APD125, a selective serotonin 5-HT2A receptor inverse agonist, significantly improves sleep maintenance in primary insomnia","volume":"31","author":"Rosenberg","year":"2008","journal-title":"Sleep"},{"issue":"4","key":"10.1016\/j.bbr.2024.115019_bib39","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1440-1819.2008.01822.x","article-title":"Chronic effect of nicotine on serotonin transporter mRNA in the raphe nucleus of rats: reversal by co-administration of bupropion","volume":"62","author":"Semba","year":"2008","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"10","key":"10.1016\/j.bbr.2024.115019_bib40","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.euroneuro.2010.05.003","article-title":"The alpha2 adrenergic receptor antagonist idazoxan, but not the serotonin-2A receptor antagonist M100907, partially attenuated reward deficits associated with nicotine, but not amphetamine, withdrawal in rats","volume":"20","author":"Semenova","year":"2010","journal-title":"Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.bbr.2024.115019_bib41","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0091-3057(01)00715-8","article-title":"Nicotinic\u2014Serotonergic interactions in brain and behaviour","volume":"71","author":"Seth","year":"2002","journal-title":"Pharmacol., Biochem., Behav."},{"key":"10.1016\/j.bbr.2024.115019_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108155","article-title":"Central 5-HT receptors and their function; present and future","volume":"177","author":"Sharp","year":"2020","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.bbr.2024.115019_bib43","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF00634151","article-title":"Smoking withdrawal symptoms in two weeks of abstinence","volume":"50","author":"Shiffman","year":"1976","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.bbr.2024.115019_bib44","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s002130100866","article-title":"Cessation of chronic nicotine administration enhances wet-dog shake responses to 5-HT2 receptor stimulation in rats","volume":"159","author":"Suemaru","year":"2001","journal-title":"Psychopharmacology"},{"issue":"5","key":"10.1016\/j.bbr.2024.115019_bib45","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1021\/jm9007328","article-title":"Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia","volume":"53","author":"Teegarden","year":"2010","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bbr.2024.115019_bib46","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0304-3959(98)00066-9","article-title":"5-HT2A receptor subtype is involved in the thermal hyperalgesic mechanism of serotonin in the periphery","volume":"76","author":"Tokunaga","year":"1998","journal-title":"Pain"},{"issue":"3","key":"10.1016\/j.bbr.2024.115019_bib47","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF00966669","article-title":"Effect of nicotine on extracellular levels of neurotransmitters assessed by microdialysis in various brain regions: role of glutamic acid","volume":"17","author":"Toth","year":"1992","journal-title":"Neurochem. Res."},{"issue":"3","key":"10.1016\/j.bbr.2024.115019_bib48","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0306-3623(83)90037-X","article-title":"Release of dopamine and 5-hydroxytryptamine from rat striatal slices following activation of nicotinic cholinergic receptors","volume":"14","author":"Westfall","year":"1983","journal-title":"Gen. Pharmacol."},{"issue":"8","key":"10.1016\/j.bbr.2024.115019_bib49","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/syn.20645","article-title":"Interactions of serotonin (5-HT)2 receptor-targeting ligands and nicotine: Locomotor activity studies in rats","volume":"63","author":"Zaniewska","year":"2009","journal-title":"Synapse"},{"issue":"2\u20133","key":"10.1016\/j.bbr.2024.115019_bib50","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejphar.2007.05.067","article-title":"Effects of the serotonin 5-HT2A and 5-HT2C receptor ligands on the discriminative stimulus effects of nicotine in rats","volume":"571","author":"Zaniewska","year":"2007","journal-title":"Eur. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.bbr.2024.115019_bib51","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.neuropharm.2010.02.006","article-title":"Effects of serotonin (5-HT)2 receptor ligands on depression-like behavior during nicotine withdrawal","volume":"58","author":"Zaniewska","year":"2010","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.bbr.2024.115019_bib52","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0006-8993(91)90402-H","article-title":"Spinal serotonin receptors mediate descending facilitation of a nociceptive reflex from the nuclei reticularis gigantocellularis and gigantocellularis pars alpha in the rat","volume":"550","author":"Zhuo","year":"1991","journal-title":"Brain Res."},{"issue":"Pt B)","key":"10.1016\/j.bbr.2024.115019_bib53","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.neuropharm.2014.11.003","article-title":"Diversity of native nicotinic receptor subtypes in mammalian brain","volume":"96","author":"Zoli","year":"2015","journal-title":"Neuropharmacology"}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016643282400175X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016643282400175X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T05:43:52Z","timestamp":1732686232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016643282400175X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":53,"alternative-id":["S016643282400175X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2024.115019","relation":{},"ISSN":["0166-4328"],"issn-type":[{"value":"0166-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nelotanserin, a selective 5-HT2A receptor inverse agonist, attenuates aspects of nicotine withdrawal but not reward in mice","name":"articletitle","label":"Article Title"},{"value":"Behavioural Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbr.2024.115019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115019"}}